{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:48:15Z","timestamp":1795067295399,"version":"4.10.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA244726"],"award-info":[{"award-number":["U54CA244726"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Department of Health & Human Services | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["5R01FD006589"],"award-info":[{"award-number":["5R01FD006589"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patient responses to autologous CD19 chimeric antigen receptor (CAR) T-cell therapies are limited by insufficient and inconsistent cellular functionality. Here, we show that controlling the precise level of stimulation during T-cell activation to accommodate individual differences in the donor cells will dictate the functional attributes of CAR-T cell products. The functionality of CAR-T cell products, consisting of a diverse set of blood samples derived from healthy donors, acute lymphoblastic leukemia (ALL), and chronic lymphocytic lymphoma (CLL) patient samples, representing a range of patient health status, is tested upon culturing on artificial antigen-presenting cell scaffolds to deliver T-cell stimulatory ligands (anti-CD3\/anti-CD28) at highly defined densities. A clear relationship is observed between the dose of stimulation, the phenotype of the T-cell blood sample prior to T-cell activation, and the functionality of the\u00a0resulting CAR-T cell products. We present a model, based on this dataset, that predicts the precise stimulation needed to manufacture a desired CAR-T cell product, given the input T-cell attributes in the initial blood sample. These findings demonstrate a simple approach to enhance CAR-T functionality by personalizing the level of stimulation during T-cell activation to enable flexible manufacturing of more consistent and potent CAR-T cells.<\/jats:p>","DOI":"10.1038\/s41467-023-36126-7","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T10:04:53Z","timestamp":1675159493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Enhancing CAR-T cell functionality in a patient-specific manner"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6999-6454","authenticated-orcid":false,"given":"David K. Y.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-6794","authenticated-orcid":false,"given":"Kwasi","family":"Adu-Berchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1340-6272","authenticated-orcid":false,"given":"Nicoletta","family":"Cieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Brockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-3145","authenticated-orcid":false,"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5054","authenticated-orcid":false,"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6299-1194","authenticated-orcid":false,"given":"David J.","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"36126_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"36126_CR2","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino, L. et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 4, 5607\u20135615 (2020).","journal-title":"Blood Adv."},{"key":"36126_CR3","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama, A. V. et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133, 1876\u20131887 (2019).","journal-title":"Blood"},{"key":"36126_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492\u2013500 (2016).","journal-title":"Leukemia"},{"key":"36126_CR5","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR\u2013T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"36126_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"36126_CR7","doi-asserted-by":"crossref","unstructured":"Bai, Z. et al. Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).","DOI":"10.1126\/sciadv.abj2820"},{"key":"36126_CR8","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"36126_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92\u2013101 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"36126_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","volume":"16","author":"S Tyagarajan","year":"2019","unstructured":"Tyagarajan, S., Spencer, T. & Smith, J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol. Ther. Methods Clin. Dev. 16, 136\u2013144 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"36126_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone, M. C. & O\u2019Doherty, U. Clinical use of lentiviral vectors. Leukemia 32, 1529\u20131541 (2018).","journal-title":"Leukemia"},{"key":"36126_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtm.2019.09.007","volume":"16","author":"MS Pampusch","year":"2020","unstructured":"Pampusch, M. S. et al. Rapid transduction and expansion of transduced T cells with maintenance of central memory populations. Mol. Ther. Methods Clin. Dev. 16, 1\u201310 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"36126_CR13","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.4049\/jimmunol.163.7.3735","volume":"163","author":"EJ Wherry","year":"1999","unstructured":"Wherry, E. J., Puorro, K. A., Porgador, A. & Eisenlohr, L. C. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163, 3735\u20133745 (1999).","journal-title":"J. Immunol."},{"key":"36126_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41596-019-0249-0","volume":"15","author":"DKY Zhang","year":"2020","unstructured":"Zhang, D. K. Y., Cheung, A. S. & Mooney, D. J. Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds. Nat. Protoc. 15, 773\u2013798 (2020).","journal-title":"Nat. Protoc."},{"key":"36126_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/ni908","volume":"4","author":"AV Gett","year":"2003","unstructured":"Gett, A. V., Sallusto, F., Lanzavecchia, A. & Geginat, J. T cell fitness determined by signal strength. Nat. Immunol. 4, 355\u2013360 (2003).","journal-title":"Nat. Immunol."},{"key":"36126_CR16","doi-asserted-by":"publisher","first-page":"998.e20","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998.e20\u20131013.e20 (2018).","journal-title":"Cell"},{"key":"36126_CR17","doi-asserted-by":"publisher","first-page":"5279","DOI":"10.4049\/jimmunol.166.8.5279","volume":"166","author":"H Appel","year":"2001","unstructured":"Appel, H., Seth, N. P., Gauthier, L. & Wucherpfennig, K. W. Anergy induction by dimeric TCR ligands. J. Immunol. 166, 5279\u20135285 (2001).","journal-title":"J. Immunol."},{"key":"36126_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1365-2567.2011.03458.x","volume":"133","author":"B Alarc\u00f3n","year":"2011","unstructured":"Alarc\u00f3n, B., Mestre, D. & Mart\u00ednez\u2010Mart\u00edn, N. The immunological synapse: a cause or consequence of T\u2010cell receptor triggering? Immunology 133, 420\u2013425 (2011).","journal-title":"Immunology"},{"key":"36126_CR19","doi-asserted-by":"publisher","first-page":"e89580","DOI":"10.1172\/jci.insight.89580","volume":"2","author":"Y Kagoya","year":"2017","unstructured":"Kagoya, Y. et al. Transient stimulation expands superior antitumor T cells for adoptive therapy. JCI Insight 2, e89580 (2017).","journal-title":"JCI Insight"},{"key":"36126_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nbt.4047","volume":"36","author":"AS Cheung","year":"2018","unstructured":"Cheung, A. S., Zhang, D. K. Y., Koshy, S. T. & Mooney, D. J. Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat. Biotechnol. 36, 160\u2013169 (2018).","journal-title":"Nat. Biotechnol."},{"key":"36126_CR21","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Investig. 115, 1616\u20131626 (2005).","journal-title":"J. Clin. Investig."},{"key":"36126_CR22","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.052676899","volume":"99","author":"LE Cheng","year":"2002","unstructured":"Cheng, L. E., \u00d6hl\u00e9n, C., Nelson, B. H. & Greenberg, P. D. Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl Acad. Sci. USA 99, 3001\u20133006 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"36126_CR23","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","volume":"8","author":"J-M Hoffmann","year":"2018","unstructured":"Hoffmann, J.-M. et al. Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients. Front. Immunol. 8, 1956 (2018).","journal-title":"Front. Immunol."},{"key":"36126_CR24","doi-asserted-by":"publisher","first-page":"e000148","DOI":"10.1136\/jitc-2019-000148","volume":"8","author":"O Itzhaki","year":"2020","unstructured":"Itzhaki, O. et al. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. J. Immunother. Cancer 8, e000148 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"36126_CR25","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res. 6, 1100\u20131109 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"36126_CR26","doi-asserted-by":"crossref","unstructured":"Slichter, C. K. et al. Distinct activation thresholds of human conventional and innate-like memory T cells. JCI Insight 1, e86292 (2016).","DOI":"10.1172\/jci.insight.86292"},{"key":"36126_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.273.5271.104","volume":"273","author":"A Viola","year":"1996","unstructured":"Viola, A. & Lanzavecchia, A. T cell activation determined by T cell receptor number and tunable thresholds. Science 273, 104\u2013106 (1996).","journal-title":"Science"},{"key":"36126_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/intimm\/12.2.205","volume":"12","author":"LB Nicholson","year":"2000","unstructured":"Nicholson, L. B., Anderson, A. C. & Kuchroo, V. K. Tuning T cell activation threshold and effector function with cross-reactive peptide ligands. Int. Immunol. 12, 205\u2013213 (2000).","journal-title":"Int. Immunol."},{"key":"36126_CR29","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"J-M Chauvin","year":"2015","unstructured":"Chauvin, J.-M. et al. TIGIT and PD-1 impair tumor antigen\u2013specific CD8+ T cells in melanoma patients. J. Clin. Investig. 125, 2046\u20132058 (2015).","journal-title":"J. Clin. Investig."},{"key":"36126_CR30","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938\u20131950 (2020).","journal-title":"J. Clin. Oncol."},{"key":"36126_CR31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/PPO.0b013e3181eb33a6","volume":"16","author":"CJ Turtle","year":"2010","unstructured":"Turtle, C. J. & Riddell, S. R. Artificial antigen presenting cells for use in adoptive immunotherapy. Cancer J. 16, 374\u2013374 (2010).","journal-title":"Cancer J."},{"key":"36126_CR32","unstructured":"MD Anderson Cancer Center, University of Texas, USA. Package of Lenti-shRNA virus using HEK293T cells. https:\/\/www.mdanderson.org\/documents\/core-facilities\/Functional%20Genomics%20Core\/Lentivirus%20production%20protocols.pdf (2018)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36126-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36126-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36126-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T10:06:51Z","timestamp":1675159611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36126-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36126"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-36126-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J.M. is an inventor on patent applications Harvard University has filed in relation to the aAPC-ms technology. That intellectual property has been licensed to Lyell Immunopharma, and D.J.M. has stock in Lyell Immunopharma. C.J.W. holds equity in BioNTech. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"506"}}